EFTA01092032Set 9
25p12,760w
most importantly, convenience as an "off-the-shelf' treatment.
The safety of the allogeneic MSCs has also been documented in a meta-analysis of published and clinical
trials. Lalu ... recently published results of a systemic review of clinical trials that used MSCs to
evaluate their safety=. The authors reviewed 2,347 publications and 37 clinical trials. These studies
recruited ... efficacy and safety profiles. In addition, a meta-analysis shows
overall safety of the MSCs. Therefore, the argument on safety and efficacy of autologous vs. allogeneic has
no scientific basis
https://www.justice.gov/epstein/files/DataSet%209/EFTA01092032.pdf
EFTA01193379Set 9
4p1,852w
vitro expansion also sham that human
cally decreased, commensurate with healed areas of nonunion MSCs do not seem to undergo malignant transformation. SW cells
by 3 months and maintained ... effects from the deliv-
ery cistern cells, minimal side effects are expected from SVF MSCs
compared with other cell types, because ,v6Cs have been shown
S ternal nonunion, although rare ... promote bone healing.
CD-14+, C090., a)73+. and CO105+ cells characteristic of
MSCs, in addition to exhibiting mesodermal capacity.' Stromal
vascular fraction cells have been studied extensively in vitro
https://www.justice.gov/epstein/files/DataSet%209/EFTA01193379.pdf